EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 21 filers reported holding EVOKE PHARMA INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $464,000 | -28.4% | 400,000 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $648,000 | +88.4% | 400,000 | 0.0% | 0.01% | +66.7% |
| Q3 2019 | $344,000 | +37.6% | 400,000 | 0.0% | 0.00% | +50.0% |
| Q2 2019 | $250,000 | -58.3% | 400,000 | 0.0% | 0.00% | -60.0% |
| Q1 2019 | $600,000 | -39.5% | 400,000 | 0.0% | 0.01% | -44.4% |
| Q4 2018 | $992,000 | -16.8% | 400,000 | 0.0% | 0.01% | 0.0% |
| Q3 2018 | $1,192,000 | +19.2% | 400,000 | 0.0% | 0.01% | +12.5% |
| Q2 2018 | $1,000,000 | +20.2% | 400,000 | 0.0% | 0.01% | +14.3% |
| Q1 2018 | $832,000 | -8.0% | 400,000 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $904,000 | -32.3% | 400,000 | 0.0% | 0.01% | -36.4% |
| Q3 2017 | $1,336,000 | +30.5% | 400,000 | 0.0% | 0.01% | +37.5% |
| Q2 2017 | $1,024,000 | +13.1% | 400,000 | +37.0% | 0.01% | +14.3% |
| Q1 2017 | $905,000 | +148.6% | 291,966 | +62.2% | 0.01% | +133.3% |
| Q4 2016 | $364,000 | +15.2% | 180,000 | +28.6% | 0.00% | +50.0% |
| Q3 2016 | $316,000 | +84.8% | 140,000 | +460.0% | 0.00% | +100.0% |
| Q2 2016 | $171,000 | – | 25,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |